The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
ADC Therapeutics, Inc. Common H0036K147 25,261 539,648 SH   SOLE   539,648 0 0
Autolus Therapeutics Limited Common 05280R100 637 39,740 SH   SOLE   39,740 0 0
Epizyme, Inc. Common 29428V104 37,444 2,331,534 SH   SOLE   2,331,534 0 0
G1 Therapeutics, Inc. Common 3621LQ109 34,541 1,423,794 SH   SOLE   1,423,794 0 0
Harpoon Therapeutics, Inc. Common 41358P106 64,714 3,898,422 SH   SOLE   3,898,422 0 0
MEI Pharma, Inc. Common 552798202 41,869 10,137,859 SH   SOLE   10,137,859 0 0
Merus N.V. Common N5749R100 11,277 700,879 SH   SOLE   700,879 0 0
Repare Therapeutics, Inc. Common 760273102 74,086 2,388,337 SH   SOLE   2,388,337 0 0
TCR2 Therapeutics, Inc. Common 87808K106 51,778 3,370,982 SH   SOLE   3,370,982 0 0
Turning Point Therapeutics, Inc. Common 90041T108 19,938 308,686 SH   SOLE   308,686 0 0
YmAbs Therapeutics, Inc. Common 984241109 14,571 337,291 SH   SOLE   337,291 0 0